LONDON
Australian mobile health technology company Global Kinetics Corporation announced today that it has appointed Swedish regulatory affairs veteran Dr Thomas Lönngren to the Board of Directors, effective immediately. The high calibre appointment is a strategic achievement for the company.
As part of an aggressive EU expansion agenda, the company also announced it has been granted a key patent protecting its assets in the high value EU market.
Managing Director and Chief Executive Officer Mr Andrew Maxwell said these latest commercial milestones are pivotal to the company’s vision to make measurable change for people with Parkinson’s Disease.
“Dr Lönngren has an impeccable background in health systems, drug, medical device regulations and in working with international Government and industry stakeholders at the highest levels. We expect his expertise to prove invaluable as we deliver value for people with Parkinson’s disease, clinicians, governments and commercial stakeholders worldwide,” he said.
Dr Lönngren commented, “During my time at the EMA I actively promoted initiatives such as mobile health technologies that could lead to improved treatment for chronic disease. It is of great importance that drug treatment is optimised considering that huge losses accrue as a result of the way we manage drug treatment today.”
Dr L önngren continued “Global Kinetics Corporation is a leader in mobile health information technology – the world leading decision support information that Global Kinetics Corporation provides will assist in clinical management of Parkinson’s disease for patients, clinicians, governments and other stakeholders leading to a reduction of a major disease burden. I am looking forward to contributing to the success of Global Kinetics Corporation as it expands its operations in Europe, the United States and throughout the rest of the world.”
The EU patent provides long term protection for the company’s ability to record, measure and assess clinical movement data in Parkinson’s patients using the proprietary PKG™ technology. It also secures proprietary mathematical algorithms associated with data analysis.
Mr Maxwell commented “It is imperative we protect our assets with a robust intellectual property portfolio and the granting of this patent marks a critical milestone as we target global commercialisation.”
These milestones also follow Global Kinetics Corporation’s agreement with lead Parkinson’s research and support charity Parkinson’s UK to make the PKG™ technology available to hundreds of patients throughout the UK as part of a pilot project to be held over the next 12 months.
The company has already secured FDA clearance, CE Mark and TGA registration for the PKG™ technology – allowing for sales in the USA, Europe and the Asia Pacific region.
About Global Kinetics Corporation
Global Kinetics Corporation (GKC) is a privately held technology company headquartered in Australia focused on globally commercialising its innovative movement disorder technology, specifically for the treatment of Parkinson’s Disease. The company’s lead product is the Parkinson’s Kinetigraph™ (PKG™), a first in class medical technology assisting neurologists to better manage the key disabling movement symptoms of Parkinson’s.
The PKG™ data logger is a wrist worn device that automatically records, analyses and reports motion data to assist doctors in their diagnosis and treatment of symptoms. This objective movement data recorded over 6 days, is downloaded within minutes and assists doctors to analyse disease progression and treatment response. Parkinson’s disease is a progressive disorder of the brain’s frontal lobe, which controls impulsive and non-impulsive movement. An estimated 6 million people around the world are affected. The main motor (or movement) related symptoms of Parkinson’s disease are bradykinesia, rigidity, tremors, postural instability and over time people with Parkinson’s may experience dyskinesias or relentless uncontrolled movements. Other non-movement symptoms may be experienced such as speech and swallowing difficulties, cognitive impairment or behavioural change and sleep disturbance.
About Dr Thomas Lönngren
Dr Lönngren has developed extensive experience in regulatory affairs in a career spanning almost 40 years. In his most prominent position he served as executive director of the European Medicine Agency for 10 years (2001-2010) where he was responsible for management of the agency and its scientific committees. Since his retirement from the EMA Dr Lönngren has worked as an independent consultant and advisor in health technology assessment and regulatory science for pharmaceutical companies and not-for-profit organisations. Dr Lonngren is also the strategy advisor to NDA Group, a EU leading regulatory and health technology assessment consulting firm.
For further information please go to www.globalkineticscorporation.com.au
CONTACT
Grayling PR
Carolyn Monchouguy
0207 592 7924
carolyn.monchouguy@grayling.com
